Replimune Group, Inc. (REPL) Stock Analysis — Probabli.AI
AI-powered analysis for REPL (Replimune Group, Inc.): probabilistic price forecasts, technical signals, peer comparison, institutional ownership, earnings history, and social sentiment. Latest AI outlook: Bullish.
Last price: $16.31 · Market cap: $1.4B · AI outlook: Bullish
Replimune Group (REPL) has achieved a transformative milestone with the U.S. regulatory approval and market launch of TUDRIQEV for advanced melanoma. This regulatory de-risking has propelled the shares significantly off their 52-week lows, moving the company from a purely clinical-stage biotech into an active commercial-stage immuno-oncology player. While short-term trading may see volatility due…
Probabilistic 1-Year Outlook
- Bull 55% · Neutral 25% · Bear 20%
- 1-year price estimates — P10: $11 / P50: $21 / P90: $29
- The commercial rollout of TUDRIQEV (RP1) for advanced melanoma provides immediate revenue visibility and validation for Replimune's oncolytic immunotherapy platform. While recent share price gains (+141% over trailing…
5-Year Outlook
- Bull 50% · Neutral 25% · Bear 25%
- 5-year price estimates — P10: $9 / P50: $42 / P90: $72
SWOT Highlights
- Strength: Regulatory approval and commercial launch of lead asset TUDRIQEV for advanced melanoma
- Strength: Proprietary engineered oncolytic immunotherapy platform (RP1, RP2, RP3) with dual mechanism of action
- Risk: Currently operating at an ongoing net cash burn with negative EPS estimates ($-0.77/share)
- Risk: Heavy near-term commercial execution reliance on a single lead product
Major Catalysts
- [object Object]
- [object Object]
- [object Object]
Analyst Coverage & Dividends
8 Wall Street analysts rate REPL a BUY with a mean price target of $19.86.
Last analyzed · Model: gemini-3.8-flash. How this forecast works · Accuracy & validation.
REPL forecast details · REPL sentiment details · REPL insider activity
Recent saved forecast research
AI-generated research records, not evaluated investment results.
- Replimune Group, Inc. (REPL) — saved
Replimune Group (REPL) has achieved a transformative milestone with the U.S. regulatory approval and market launch of TUDRIQEV for advanced melanoma. This regulatory de-risking has propelled the shares significantly off their 52-week lows,
- Replimune Group, Inc. (REPL) — saved
Replimune Group, Inc., currently priced at $11.47, is showing promising developments in its oncolytic virus therapy pipeline, supported by positive trial results and significant funding. However, regulatory challenges and cautious analyst s
The information on this page is for educational and informational purposes only and does not constitute professional financial advice.